

Pharmacy Benefact

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS

Number 866 • June 2020

Product supply shortage addressed for *Alberta Human Services Drug Benefit Supplement (HSDBS)*

Alberta Blue Cross has been advised by Odan Laboratories Ltd. that the shortage for Ferodan 75 mg/ml Infant Drops (NPN 02237385) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **July 8, 2020**.

FERROUS SULFATE

75 MG/ML DROPS

00002237385	FERODAN INFANT	ODN	\$ 0.1432
00000762954	FER-IN-SOL	MJO	\$ 0.2558

Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Auro Pharma Inc., Sivem Pharmaceuticals ULC, and Pharmascience Inc. that the shortages for Auro-Losartan HCT 100 mg/25 mg Tablet (DIN 02423669), Losartan/HCT 100 mg/25 mg Tablet (DIN 02388987), pms-Losartan-HCTZ 100 mg/25 mg Tablet (DIN 02392240), respectively have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **July 9, 2020**.

LOSARTAN POTASSIUM/ HYDROCHLOROTHIAZIDE

100 MG / 25 MG TABLET

00002423669	AURO-LOSARTAN HCT	AUR	\$ 0.3146
00002408252	JAMP-LOSARTAN HCTZ	JPC	\$ 0.3146
00002388987	LOSARTAN/HCT	SIV	\$ 0.3146
00002427664	LOSARTAN/HCTZ	SNS	\$ 0.3146
00002389673	MINT-LOSARTAN/HCTZ DS	MPI	\$ 0.3146
00002392240	PMS-LOSARTAN-HCTZ	PMS	\$ 0.3146
00002313383	SANDOZ LOSARTAN HCT DS	SDZ	\$ 0.3146
00002428547	SEPTA-LOSARTAN HCTZ	SEP	\$ 0.3146
00002377152	TEVA-LOSARTAN/HCTZ	TEV	\$ 0.3146
00002241007	HYZAAR DS	MFC	\$ 1.4140

continued on next page ...

... continued from previous page

Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Auro Pharma Inc., Sivem Pharmaceuticals ULC, and Pharmascience Inc. that the shortages for Auro-Losartan HCT 50 mg/12.5 mg Tablet (DIN 02423642), Losartan/HCT 50 mg/12.5 mg Tablet (DIN 02388960), pms-Losartan-HCTZ 50 mg/12.5 mg Tablet (DIN 02392224), respectively have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **July 13, 2020**.

LOSARTAN POTASSIUM/ HYDROCHLOROTHIAZIDE

50 MG / 12.5 MG TABLET

00002423642	AURO-LOSARTAN HCT	AUR	\$ 0.3146
00002408244	JAMP-LOSARTAN HCTZ	JPC	\$ 0.3146
00002388960	LOSARTAN/HCT	SIV	\$ 0.3146
00002427648	LOSARTAN/HCTZ	SNS	\$ 0.3146
00002389657	MINT-LOSARTAN/HCTZ DS	MPI	\$ 0.3146
00002392224	PMS-LOSARTAN-HCTZ	PMS	\$ 0.3146
00002313375	SANDOZ LOSARTAN HCT DS	SDZ	\$ 0.3146
00002428539	SEPTA-LOSARTAN HCTZ	SEP	\$ 0.3146
00002358263	TEVA-LOSARTAN/HCTZ	TEV	\$ 0.3146
00002230047	HYZAAR DS	MFC	\$ 1.4140

Alberta Blue Cross has been advised by Omega Laboratories Limited that the shortage for Octreotide Acetate Omega 200 mcg/ml Injection (DIN 02248642) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **July 13, 2020**.

OCTREOTIDE ACETATE

200 MCG / ML INJECTION

00002248642	OCTREOTIDE ACETATE OMEGA	OMG	\$ 6.3420
00002049392	SANDOSTATIN	NOV	\$ 18.6861

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php

